% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Grassl:283125,
      author       = {N. Grassl$^*$ and I. Poschke$^*$ and K. Lindner$^*$ and L.
                      Bunse$^*$ and I. Mildenberger$^*$ and T. Boschert$^*$ and K.
                      Jähne$^*$ and E. W. Green$^*$ and I. Hülsmeyer$^*$ and S.
                      Jünger$^*$ and T. Kessler and A. K. Suwala$^*$ and P.
                      Eisele and M. Breckwoldt$^*$ and P. Vajkoczy and O. M.
                      Grauer and U. Herrlinger and J.-C. Tonn and M. Denk and F.
                      Sahm$^*$ and M. Bendszus and A. von Deimling$^*$ and F.
                      Winkler and W. Wick and M. Platten$^*$ and K. Sahm$^*$},
      title        = {{A} {H}3{K}27{M}-targeted vaccine in adults with diffuse
                      midline glioma.},
      journal      = {Nature medicine},
      volume       = {29},
      number       = {10},
      issn         = {1078-8956},
      address      = {New York, NY},
      publisher    = {Nature America Inc.},
      reportid     = {DKFZ-2023-01912},
      pages        = {2586-2592},
      year         = {2023},
      note         = {#EA:D170#LA:D170# / 2023 Oct;29(10):2586-2592 / HI-TRON},
      abstract     = {Substitution of lysine 27 to methionine in histone H3
                      (H3K27M) defines an aggressive subtype of diffuse glioma.
                      Previous studies have shown that a H3K27M-specific long
                      peptide vaccine (H3K27M-vac) induces mutation-specific
                      immune responses that control H3K27M+ tumors in major
                      histocompatibility complex-humanized mice. Here we describe
                      a first-in-human treatment with H3K27M-vac of eight adult
                      patients with progressive H3K27M+ diffuse midline glioma on
                      a compassionate use basis. Five patients received H3K27M-vac
                      combined with anti-PD-1 treatment based on physician's
                      discretion. Repeat vaccinations with H3K27M-vac were safe
                      and induced CD4+ T cell-dominated, mutation-specific immune
                      responses in five of eight patients across multiple human
                      leukocyte antigen types. Median progression-free survival
                      after vaccination was 6.2 months and median overall survival
                      was 12.8 months. One patient with a strong mutation-specific
                      T cell response after H3K27M-vac showed pseudoprogression
                      followed by sustained complete remission for >31 months. Our
                      data demonstrate safety and immunogenicity of H3K27M-vac in
                      patients with progressive H3K27M+ diffuse midline glioma.},
      cin          = {D170 / B300 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)D170-20160331 / I:(DE-He78)B300-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37735561},
      doi          = {10.1038/s41591-023-02555-6},
      url          = {https://inrepo02.dkfz.de/record/283125},
}